// App-Quantinova.ai

: Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Amber C. King

Principal Investigators

  • Jeremy Pappacena

  • Martin S. Tallman

  • Jae H. Park

  • Mark Blaine Geyer

Medical Centers

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved